Clinical studies of Huoxuetongluo granula on the treatment of ischemic optic neuropathy

Abstract

AIM: To evaluate the clinical efficacy of Huoxuetongluo granula on the treatment of qi deficiency and blood stasis type of non-arteritic anterior ischemic optic neuropathy(NAION). METHODS: A total of 100 patients with NAION were enrolled in the randomized controlled trial. They were divided into control group(49 cases with 70 eyes)and treatment group(51 cases with 72 eyes). The patients in control group were treated with only injections of compound anisodine(CA)beside superficial temporal artery,2ml each time, once per day. The patients in treatment group received huoxuetongluo granula, 10g each time, twice per days, besides CA. Patients were followed up for 3mo, and the overall cure effect, visual acuity, mean sensitivity(MS), serum lipid levels and hemorheology indicators were measured and analyzed. RESULTS: After treatments, the total effective rate of treatment group were 88.2%, which was significantly higher than that of the control group(71.4%)(Z=2.890,P=0.004). Compared with the control group, the visual acuity and MS of treatment group were significantly higher and the differences were statistical(t=-4.65,Pt=-3.69,P=0.0004). The TC, TG and low-density lipoprotein cholesterol(LDL-C)levels were significantly lower, the high-density lipoprotein cholesterol(HDL-C)significantly increased than those before treatments(t=6.25, Pt=4.14,Pt=4.48, Pt=3.76, P=0.0003; t=-4.31, Pt=3.40, P=0.0011; t=5.75; Pt=3.61, P=0.0005; t=6.78, Pt=3.13, P=0.0025). CONCLUSION: The combination of CA and huoxuetongluo granula can improve the visual acuity, MS, serum lipid levels and hemorheology indicators significantly.

Keywords

• optic neuropathy
• hemorheology
• huoxuetongluo granula